03Apr/13

Lonza Reaffirms Commitment to Teva Biosimilars JV in Light of 'Inaccurate … – In-PharmaTechnologist.com


In-PharmaTechnologist.com

Lonza Reaffirms Commitment to Teva Biosimilars JV in Light of ‘Inaccurate
In-PharmaTechnologist.com
News of the strategy review follows a few months after Teva halted a Phase III trial of TL011 , a biosimilar version of Swiss drugmaker Roche’s Rituxan/MabThera (rituximab). According to a report in Israeli newspaper Haaretz at the time development was

03Apr/13

Biogen Idec completa la adquisición de todos los derechos y control de TYSABRI® – Lainformacion.com

Biogen Idec completa la adquisición de todos los derechos y control de TYSABRI®
Lainformacion.com
Biogen Idec también cuenta con la cartera de EM más completa del sector con compuestos que incluyen PLEGRIDY (peginterferón beta-1a); el proceso de alto rendimiento de daclizumab (DAC HYP) para la administración subcutánea mensual; y un estudio

and more »

03Apr/13

Messi scare puts spotlight on Barca's misfiring strikers – Times of India


IANS

Messi scare puts spotlight on Barca’s misfiring strikers
Times of India
The versatile Eric Abidal has just returned to the side a year after having a liver transplant and has yet to play a competitive match. Another option is to convert holding midfielders Sergio Busquets or Alex Song into centre-backs, which has been
Barcelona may well win the battle, but decimated defence means they might not Goal.com India
Messi, Mascherano hurt as Barca play draw in ParisIANS

all 675 news articles »